Announcement PDF RNS Number : 1379N Pharma C Investments PLC 28 September 2021 28 September 2021 Pharma C Investments Plc ("Pharma C" or the "Company") Interim Results Pharma C Investments (AQSE: PCIL), an early-stage investor and venture builder in the medical cannabis industry with a particular focus on companies that provide ancillary products and services to the medicinal cannabis sectors, announces its interim results for the period ended 30 June 2021. Highlights • • • • Admitted to London's AQSE Growth Market ("Admission") in May 2021 £1 million fundraise at Admission Appointed Toby Shillito to the Board as Chief Business Development Officer Focusing on developing a proper process to funnel and assess a pipeline of fairly priced, promising companies engaged in the ancillary medical cannabis sector Chair's Statement I am honoured to be reporting our first set of results as a listed company on the AQSE Growth Market. This year has been a challenging one for many reasons, but I am proud of all the hard work that went in to ensuring Pharma C was able to achieve a successful fundraise and Admission in May this year. Since going public, the Board has been focusing on shortlisting a number of deals in the ancillary space and sourcing the right investment. There is a pipeline and the management team are concentrating on delivering the right investment for our shareholders. In order to facilitate this process, Pharma C welcomed Toby Shillito to the Board team as Chief Business Development Officer. Toby provides a wealth of experience across the medical cannabis industry and has been a key addition to the team in helping us identify relevant investment opportunities and evaluate them in line with our strict investment thesis. As per our strategy, we are pursuing investment opportunities in the United Kingdom, Europe and Israel, the latter renowned as a global leader and innovator in cannabis and where the Board has significant expertise. The ancillary sector offers an attractive opportunity, allowing investors to play a key role in a growing industry without infringing on any restrictive cannabis legislation. Ancillary businesses are generally viewed as more stable than those which are plant-touching. Given the phenomenal uptake in this rapid growth sector, ancillary businesses who serve the medical cannabis community are well placed to capitalise on the need for advice around regulations, tools and ag-tech to grow consistent crop, innovation for synthetic cannabinoid products and facilitate the growth of the general marketplace of this industry. I would like to thank our shareholders for their continued support, and I look forward to providing the market with an update on our first investment in the near future. Financial Results UNAUDITED PROFIT AND LOSS ACCOUNT for the six months ended 30 June 2021 6 months to 30 June 2021 6 months to 30 June 2020 (unaudited) (unaudited) £'000 £'000 - - Administrative expenses (247) (9) Loss on ordinary activities before taxation (247) (9) - - Loss on ordinary activities after taxation (247) (9) Retained loss for the period (247) (9) Turnover Tax on loss on ordinary activities Loss per ordinary share (pence) (0.17p) (0.00p) UNAUDITED BALANCE SHEET as at 30 June 2021 30 June 2021 31 Dec 2020 (unaudited) (audited) £'000 £'000 Debtors and prepayments 5 7 Cash at Bank and in hand 759 8 764 15 Creditors: amounts falling due within one year (23) (37) Net current assets 741 (22) Total assets less current liabilities 741 (22) Net assets 741 (22) Called up share capital 674 247 Share Premium 583 - Profit and loss account (516) (269) Equity shareholder funds 741 (22) Current Assets Capital and reserves UNAUDITED STATEMENT OF CHANGES IN EQUITY for the 6 months ended 30 June 2021 No of shares Share Share Retained Total At 30 June 2020 99,000,001 capital premium earnings £'000 £'000 £'000 £'000 247 0 (9) 238 (260) (260) Loss for 6 months Issue of new shares At 31 December 2020 0 0 0 99,000,001 247 0 0 Loss for 6 months Issue of new shares 170,857,143 427 Share issue costs At 30 June 2021 269,857,144 674 (269) (22) (247) (247) 643 1070 (60) (60) 583 (516) 741 UNAUDITED STATEMENT OF CASH FLOW for the period ended 30 June 2021 Unaudited period ended 30 June 21 £'000 Unaudited period ended 30 June 20 £'000 (247) (9) (Increase)/decrease in trade and other receivables 2 0 (Decrease)/increase in trade and other payables (14) 0 (259) (9) 1,070 0 Operating activities Loss after tax Net cash (outflow)/inflow from operating activities Finance activities Proceeds from the issue of share capital Share issue costs (60) 0 Net cash inflow from financing activities 1,010 0 Net change in cash and cash equivalents 751 (9) Cash and cash equivalents at beginning of period 8 44 Cash and cash equivalents at end of period 759 35 Notes to the interim results 1. The interim results together with the related notes set out below have been approved by the board of directors of the Company. 2. No interim results were published for the period ended 30 June 2020. 3. These financial results are unaudited and do not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006 nor have they been reviewed by the auditors of the Company. 4. The interim results have been prepared using the accounting policies set out in the statutory accounts for the year ended 31 December 2020. 5. Loss per share - the earnings per share for the six months ended 30 June 2021 have been calculated on the basis of the loss after taxation for the period of £247,000 and the weighted average number of shares in issue during the period of 141,768,718. - Ends For additional information please contact: Pharma C Investments Tel: +44 7897 834 092 Chana Greenberg, CEO Novum Securities (AQSE Corporate Adviser) Tel: +44 207 399 9400 chana@pharmacinvestments.com David Coffman / Lucy Bowden Blytheweigh Tel: +44 207 138 3204 (Financial PR/IR-London) Tim Blythe tim.blythe@blytheweigh.com Megan Ray megan.ray@blytheweigh.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NEXKDLFLFKLLBBD